Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1993 3
1994 2
1995 6
1996 1
1998 3
1999 3
2000 2
2001 6
2002 6
2003 5
2004 7
2005 8
2006 6
2007 5
2008 5
2009 6
2010 6
2011 4
2012 7
2013 9
2014 3
2015 3
2016 5
2017 4
2018 1
2019 2
2020 4
2021 5
2022 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

120 results

Results by year

Filters applied: . Clear all
Page 1
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Lynch TJ, et al. Among authors: supko jg. N Engl J Med. 2004 May 20;350(21):2129-39. doi: 10.1056/NEJMoa040938. Epub 2004 Apr 29. N Engl J Med. 2004. PMID: 15118073 Free article.
Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001.
Vrooman LM, Blonquist TM, Stevenson KE, Supko JG, Hunt SK, Cronholm SM, Koch V, Kay-Green S, Athale UH, Clavell LA, Cole PD, Harris MH, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Place AE, Schorin MA, Welch JJG, Neuberg DS, Sallan SE, Silverman LB. Vrooman LM, et al. Among authors: supko jg. J Clin Oncol. 2021 Nov 1;39(31):3496-3505. doi: 10.1200/JCO.20.03692. Epub 2021 Jul 6. J Clin Oncol. 2021. PMID: 34228505 Clinical Trial.
A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma.
Blum KA, Supko JG, Maris MB, Flinn IW, Goy A, Younes A, Bobba S, Senderowicz AM, Efuni S, Rippley R, Colak G, Trojer P, Abramson JS. Blum KA, et al. Among authors: supko jg. Cancer Res Commun. 2022 Aug 11;2(8):795-805. doi: 10.1158/2767-9764.CRC-22-0060. eCollection 2022 Aug. Cancer Res Commun. 2022. PMID: 36923307 Free PMC article. Clinical Trial.
Multimodal platform for assessing drug distribution and response in clinical trials.
Lopez BGC, Kohale IN, Du Z, Korsunsky I, Abdelmoula WM, Dai Y, Stopka SA, Gaglia G, Randall EC, Regan MS, Basu SS, Clark AR, Marin BM, Mladek AC, Burgenske DM, Agar JN, Supko JG, Grossman SA, Nabors LB, Raychaudhuri S, Ligon KL, Wen PY, Alexander B, Lee EQ, Santagata S, Sarkaria J, White FM, Agar NYR. Lopez BGC, et al. Among authors: supko jg. Neuro Oncol. 2022 Jan 5;24(1):64-77. doi: 10.1093/neuonc/noab197. Neuro Oncol. 2022. PMID: 34383057 Free PMC article.
Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours.
Konstantinopoulos PA, Cheng SC, Supko JG, Polak M, Wahner-Hendrickson AE, Ivy SP, Bowes B, Sawyer H, Basada P, Hayes M, Curtis J, Horowitz N, Wright AA, Campos SM, Ivanova EV, Paweletz CP, Palakurthi S, Liu JF, D'Andrea AD, Gokhale PC, Chowdhury D, Matulonis UA, Shapiro GI. Konstantinopoulos PA, et al. Among authors: supko jg. Br J Cancer. 2022 Apr;126(7):1027-1036. doi: 10.1038/s41416-021-01664-8. Epub 2021 Dec 9. Br J Cancer. 2022. PMID: 34887522 Free PMC article. Clinical Trial.
Metabolic inhibition of galectin-1-binding carbohydrates accentuates antitumor immunity.
Cedeno-Laurent F, Opperman MJ, Barthel SR, Hays D, Schatton T, Zhan Q, He X, Matta KL, Supko JG, Frank MH, Murphy GF, Dimitroff CJ. Cedeno-Laurent F, et al. Among authors: supko jg. J Invest Dermatol. 2012 Feb;132(2):410-20. doi: 10.1038/jid.2011.335. Epub 2011 Dec 8. J Invest Dermatol. 2012. PMID: 22158550 Free PMC article.
Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses.
Brown JR, Walker SR, Heppler LN, Tyekucheva S, Nelson EA, Klitgaard J, Nicolais M, Kroll Y, Xiang M, Yeh JE, Chaudhury M, Giaccone ZT, Fernandes SM, Jacobsen ED, Fisher DC, Freedman AS, Davids MS, Supko JG, Wu C, Frank DA. Brown JR, et al. Among authors: supko jg. Am J Hematol. 2021 Apr 1;96(4):E95-E98. doi: 10.1002/ajh.26084. Epub 2021 Jan 11. Am J Hematol. 2021. PMID: 33373063 Free PMC article. Clinical Trial. No abstract available.
Tumor suppression by small molecule inhibitors of translation initiation.
Chen L, Aktas BH, Wang Y, He X, Sahoo R, Zhang N, Denoyelle S, Kabha E, Yang H, Freedman RY, Supko JG, Chorev M, Wagner G, Halperin JA. Chen L, et al. Among authors: supko jg. Oncotarget. 2012 Aug;3(8):869-81. doi: 10.18632/oncotarget.598. Oncotarget. 2012. PMID: 22935625 Free PMC article.
120 results